相关实验视频

Updated: Jun 9, 2025

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

外源IL-33通过宏观调节ILC2s促进瘤免疫力

Zhenchu Feng¹, Ye Kuang², Yuan Qi³

¹Department of Surgery, The 2nd Affiliated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, 150086, China.

Scientific reports

|October 31, 2024

概括

外源性介质素-33 (IL-33) 通过减少中性粒细胞和增加乙氨基粒细胞和2组先天性淋巴细胞 (ILC2) 来抑制黑色素瘤. 这增强了抗瘤免疫力,为新的癌症免疫疗法提供了潜力.

科学领域:

免疫学免疫学免疫学
癌症生物学癌症生物学
分子生物学分子生物学

背景情况:

介素-33 (IL-33) 是一种具有多种生物功能的类细胞因子.
外源IL-33对瘤免疫微环境的影响尚未完全理解.
黑色素瘤的进展受瘤微环境内的免疫细胞复杂相互作用的影响.

研究的目的:

为了研究外源IL-33对瘤免疫微环境在皮下黑色素瘤的影响.
阐明IL-33调节免疫细胞群和抗瘤反应的机制.
探索IL-33作为黑色素瘤治疗剂的潜力.

主要方法:

单细胞RNA测序 (scRNA-seq) 用于分析免疫细胞组成和基因表达.
流细胞计量用于量化免疫细胞种群,包括乙氨基和ILC2s.
使用Il7r^CreArg1^flox/flox小鼠进行基因操纵,以评估ILC2s的作用.

主要成果:

外源性IL-33的使用抑制了黑色素瘤的进展,并减少了中性粒细胞的积累.
在瘤微环境中,IL-33治疗显著增加了乙氨基和2组先天性淋巴细胞 (ILC2) 的比例.
发现ILC2s表达主要基因相容性复合体 (MHC) II类分子的基因,这表明它在抗原呈现中的作用.
ILC2s对于IL-33诱导的异氨基细胞增加至关重要,正如在Il7r^CreArg1^flox/flox小鼠中所示.
外源IL-33促进了ILC2的分化和积累,从而增强了抗瘤免疫反应.

结论:

外源IL-33通过重新编程免疫微环境,在黑色素瘤中表现出强大的抗瘤作用.
IL-33通过扩张和激活ILC2s和eosinophils来增强抗瘤免疫力.
ILC2s在IL-33介导的抗瘤反应中发挥着关键作用,可能通过抗原呈现.
这些发现支持开发基于IL-33的癌症免疫疗法,以增强抗瘤免疫反应.

关键词:

瘤的免疫微环境癌症免疫力免疫力免疫疗法免疫疗法介质蛋白-33 介质蛋白-33 2型的先天性淋巴细胞.

更多相关视频

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice

Published on: January 25, 2017

A Strategy for the Study of IL-9-Producing Lymphoid Cells in the Nippostrongylus brasiliensis Infection Model

A Strategy for the Study of IL-9-Producing Lymphoid Cells in the Nippostrongylus brasiliensis Infection Model

Published on: March 3, 2023

相关概念视频

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...